Drug Trial Radar · NCT04592653
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Sep 30, 2020
Primary completion
Jul 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Mural Oncology, IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).
Conditions
- Advanced Solid Tumor
Interventions
Nemvaleukin alfaBiological
IV infusion over 30 minutes
PembrolizumabBiological
IV infusion over 30 minutes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in density (cell counts per mm2) of immune cell (including total T cells, CD8+ T cells, CD56+ cells and Treg cells)Time frame: From the time of the Patient's pre-treatment biopsy to the time of the Patient's on-treatment biopsy
- Changes in ratios (including T/Treg, CD8+/Treg, CD56+/Treg) based on immunohistochemistry (IHC) and/or immunofluorescence (IF) in the TME between pretreatment and on-treatment (Cycle 2 Day 8) paired tumor biopsiesTime frame: From the time of the Patient's pre-treatment biopsy to the time of the Patient's on-treatment biopsy
- Incidence of dose-limiting toxicity (DLT)Time frame: From the first dose through end of dose-limiting toxicity observation period (up to 24 months)
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
START Midwest
Grand Rapids, Michigan
MD Anderson Cancer Center
Houston, Texas
START Mountain
West Valley City, Utah
NEXT Virginia
Fairfax, Virginia
Hospital Clinico San Carlos
Madrid, Spain
CIOCC HM Sanchinarro
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.